TMS-19-Q・O錠の浅在性化膿性疾患に対する基礎的・臨床的検討

久木田 淳; 野波 英一郎; 田上 八朗; 占部 治邦; 中川 秀己; 滝脇 弘嗣; 高橋 久; 月永 一郎; 武田 克之; 藤田 恵一; 瀧澤 清宏; 戸田 浄; 山田 清; 井村 真; 星野 学; 田代 正昭; 野原 望; 関根 るみ子; 荒瀬 誠治; 梅村 茂夫; 野元 茂; 渡辺 晋一; 島田 真路; 米良 修二; 塙 伸太郎; 紫芝 敬子; 影下 登志郎; 山野 龍文; 荒尾 龍喜; 朝田 康夫; 谷田 泰男; 木村 康隆; 三浦 祐晶

doi:10.11553/antibiotics1968b.38.575

CLINICAL AND BACTERIOLOGICAL EVALUATION OF TMS-19-Q IN SUPERFICIAL SUPPURATIVE SKIN AND SOFT TISSUE INFECTION

ATSUSHI KUKITA, EIICHIRO NONAMI, HACHIRO TAGAMI, HARUKUNI URABE, HIDEMI NAKAGAWA, HIROTSUGU TAKIWAKI, HISASHI TAKAHASHI, ICHIRO TSUKINAGA, KATSUYUKI TAKEDA, KEIICHI FUJITA, KIYOHIRO TAKIZAWA, KIYOSHI TODA, KIYOSHI YAMADA, MAKOTO IMURA, MANABU HOSHINO, MASAAKI TASHIRO, NOZOMI NOHARA, RUMIKO SEKINE, SEIJI ARASE, SHIGEO UMEMURA, SHIGERU NOMOTO, SHINICHI WATANABE, SHINJI SHIMADA, SHUJI MERA, SINTARO HANAWA, TAKAKO SHISHIBA, TASHIRO KAGESHITA, TATSUFUMI YAMANO, TATSUYOSHI ARAO, YASUO ASADA, YASUO TANITA, YASUTAKA KIMURA, YUSHO MIURA

Author information

ATSUSHI KUKITA
Department of Dermatology, Faculty of Medicine, Tokyo University
EIICHIRO NONAMI
Department of Dermatology, Kanto Teishin Hospital
HACHIRO TAGAMI
Department of Dermatology, School of Medicine, Tohoku University
HARUKUNI URABE
Department of Dermatology, Faculty of Medicine, Kyushu University
HIDEMI NAKAGAWA
Department of Dermatology, Faculty of Medicine, Tokyo University
HIROTSUGU TAKIWAKI
Department of Dermatology, School of Medicine, Tokushima University
HISASHI TAKAHASHI
Department of Dermatology, School of Medicine, Teikyo University
ICHIRO TSUKINAGA
Department of Dermatology, School of Medicine, Hokkaido University
KATSUYUKI TAKEDA
Department of Dermatology, School of Medicine, Tokushima University
KEIICHI FUJITA
Department of Dermatology, National Defense Medical College
KIYOHIRO TAKIZAWA
Department of Dermatology, Faculty of Medicine, Tokyo University
KIYOSHI TODA
Department of Dermatology, Tokyo Teishin Hospital
KIYOSHI YAMADA
Department of Dermatology, Faculty of Medicine, Tokyo University
MAKOTO IMURA
Department of Dermatology, Tokyo Teishin Hospital
MANABU HOSHINO
Department of Dermatology, School of Medicine, Teikyo University
MASAAKI TASHIRO
Department of Dermatology, Faculty of Medicine, Kagoshima University
NOZOMI NOHARA
Department of Dermatology, Okayama University Medical School
RUMIKO SEKINE
Department of Dermatology, National Defense Medical College
SEIJI ARASE
Department of Dermatology, School of Medicine, Tokushima University
SHIGEO UMEMURA
Department of Dermatology, Okayama University Medical School
SHIGERU NOMOTO
Department of Dermatology, Faculty of Medicine, Kagoshima University
SHINICHI WATANABE
Department of Dermatology, Faculty of Medicine, Tokyo University
SHINJI SHIMADA
Department of Dermatology, Faculty of Medicine, Tokyo University
SHUJI MERA
Department of Dermatology, Faculty of Medicine, Kagoshima University
SINTARO HANAWA
Department of Dermatology, School of Medicine, Teikyo University
TAKAKO SHISHIBA
Department of Dermatology, Kanto Teishin Hospital
TASHIRO KAGESHITA
Department of Dermatology, Kumamoto University Medical School
TATSUFUMI YAMANO
Department of Dermatology, Faculty of Medicine, Kyushu University
TATSUYOSHI ARAO
Department of Dermatology, Kumamoto University Medical School
YASUO ASADA
Department of Dermatology, Kansai Medical University
YASUO TANITA
Department of Dermatology, School of Medicine, Tohoku University
YASUTAKA KIMURA
Department of Dermatology, National Defense Medical College
YUSHO MIURA
Department of Dermatology, School of Medicine, Hokkaido University

JOURNAL FREE ACCESS

1985 Volume 38 Issue 3 Pages 575-594

DOI https://doi.org/10.11553/antibiotics1968b.38.575

Details

Abstract

Clinical effectiveness of TMS-19-Q, a new macrolide antibiotic, was evaluated in superficial infectious diseases classified into 6 groups at 13 departments of dermatology. The results obtained were as follows:
1. Final global improvement rating in 311 cases were excellent in 91, good in 158, fair in 45 and poor in 17 and the effective rate was 80.1%.
2. Effective rates in each group were 71.1% in 1st group (folliculitis and acne pustulosa), 78.6%. in 2nd group (furuncle, furunculosis and carbuncle), 100% in 3rd group (impetigo), 76.9% in 4th group (phlegmone, superficial lymphangitis, erysipelas and infectious paronychia), 88.7% in 5th group (inflammatory atheroma, subcutaneous abscess, hidradenitis suppurative and acne conglobata) and 77.3% in 6th group (secondary infection).
3. Dominant strains isolated were S. aureus (40.7%), S. epidermidis (26.9%) and anaerobic bacteria (20.8%). S. aureus was frequently isolated from most of all disease. On the other hand, S. epidermidis and anaerobic bacteria were isolated mainly from 1st and 5th group.
4. Optimum daily doses would be over 600mg.
5. Slight adverse reactions such as gastrointestinal disorders, eruption and malaise were observed in 12 cases.

Corresponding author

Register with J-STAGE for free!